Literature DB >> 6605803

Immunohistochemical study with monoclonal antibodies on immune response in human lung cancers.

S Watanabe, Y Sato, T Kodama, Y Shimosato.   

Abstract

Fifty consecutively resected lungs in the National Cancer Center of Japan were studied immunohistochemically using monoclonal antibodies (B1, B2, Leu4, Leu3a, Leu2a, Leu7, OKT6, OKM1, OKI1, OKT9) with special reference to infiltrating lymphocytes and histiocytes. The histological types of these cases were: 14 squamous cell carcinomas; 23 adenocarcinomas; four adenosquamous carcinomas; three large cell carcinomas; one small cell carcinoma with areas of large cell component; one carcinoid; and four nonneoplastic focal lesions. A large number of lymphocytes and histiocytes was present in the tumor stroma, especially in papillary adenocarcinoma, in which close association between increased OKT6-positive T-zone histiocytes (Langerhans' cells and their precursors) and proliferation of Leu3a-positive helper-inducer T-lymphocytes was conspicuous. B1-positive primary follicles were occasionally associated with proliferation of Leu3a-positive T-lymphocytes. These features correlated to regional lymph node reaction. Leu7-positive natural killer cells were present sparsely, and there was no suggestion of any significant contact with either neoplastic cells or inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605803

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining.

Authors:  Y Sato; K Mukai; S Watanabe; M Goto; Y Shimosato
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

2.  Tumour volume and macroscopic growth pattern of bronchogenic carcinoma.

Authors:  K Kayser; H Toomes; H H Vollhaber; H U Burkhardt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

3.  Defense mechanism and macroscopic tumor growth in lung tissue.

Authors:  K Kayser; W Ebert; N M Merkle; H D Becker
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Immunohistochemical characterization of HLA-DR-antigen positive dendritic cells in phaeochromocytomas and paragangliomas as a prognostic marker.

Authors:  M Furihata; Y Ohtsuki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  S-100 protein-positive Langerhans cells in various human lung cancers, especially in peripheral adenocarcinomas.

Authors:  T Nakajima; T Kodama; M Tsumuraya; Y Shimosato; T Kameya
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

6.  In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters.

Authors:  T An; U Sood; T Pietruk; G Cummings; K Hashimoto; J D Crissman
Journal:  Am J Pathol       Date:  1987-07       Impact factor: 4.307

7.  Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers.

Authors:  A Tazi; F Bouchonnet; M Grandsaigne; L Boumsell; A J Hance; P Soler
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

8.  Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis.

Authors:  L Håkansson; G Adell; B Boeryd; F Sjögren; R Sjödahl
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms.

Authors:  A Csiba; H L Whitwell; M Moore
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

10.  Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumour cells and infiltrating leucocytes.

Authors:  A Ferguson; M Moore; H Fox
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.